¿Ozempic o cirugía? Cómo decidir qué es lo adecuado para su cuerpo

Right now, there are two treatments that can genuinely change the course of your life if you're living with obesity. One is a weekly injection. It can help you lose somewhere around 15 to 21 percent of your body weight. The other is a surgery — and it can help you lose 25 to 35 percent. Both of them work. Both of them are backed by serious science. And thanks to recent price drops, both of them are more accessible than they've ever been.

But here's the thing nobody's really telling you. The "right" answer is completely different depending on who you are. Your body. Your health. Your finances. Your life situation. It's not one-size-fits-all. And by the end of this video, you're going to understand both options well enough to have a real, informed conversation with your doctor about which path makes sense for you.

Let me ground this for a second. Obesity affects 42 percent of American adults. That's not a small number. And it's not a willpower problem — it's a chronic, relapsing disease, just like high blood pressure or diabetes. And just like those diseases, it has real medical treatments. Today we're going to break down the two most powerful ones, head to head. No hype. No agenda. Just the evidence.

Lets get into it.

What Are We Actually Talking About? The Basics

Okay, so before we compare anything, let's make sure we're all on the same page about what these treatments actually are.

First — GLP-1 medications. You've probably heard of Ozempic, Wegovy, Mounjaro, Zepbound. These are all in this family. The way they work is actually pretty elegant. Your gut naturally makes a hormone called GLP-1. When you eat, this hormone tells your brain you're full, it slows down how fast your stomach empties, and it helps your body release insulin more effectively. What these medications do is mimic that hormone — but at much higher levels than your body normally produces. So your appetite goes down. You feel satisfied sooner. You eat less without feeling like you're white-knuckling it.

Now, the big names you should know. Semaglutide — that's the drug in Ozempic and Wegovy. Tirzepatide — that's Mounjaro and Zepbound. Tirzepatide is actually a little different because it targets two hormones, not just one. It hits both GLP-1 and another hormone called GIP. That dual action is why it tends to be the most potent medication in this class. There's also liraglutide, which is sold as Saxenda — it was one of the earlier ones, still used, but not quite as powerful as the newer options.

Now let's talk surgery. There are two main procedures that account for the vast majority of bariatric surgeries done today. The first is the sleeve gastrectomy. This is where the surgeon removes about 85 percent of your stomach, leaving behind a narrow tube — kind of shaped like a banana. It's permanent. Your stomach is physically smaller, so you eat less, but it also changes your gut hormones in ways that reduce hunger.

The second is the Roux-en-Y gastric bypass. This one's a bit more complex. The surgeon creates a small pouch at the top of your stomach — about the size of an egg — and then connects it directly to the middle part of your small intestine, bypassing a big section of your digestive tract. So you eat less AND you absorb fewer calories. It's been around for decades and has a massive amount of long-term data behind it.

Both of these surgeries are now done laparoscopically or even robotically. We're talking small incisions, minimally invasive, usually a one- to two-night hospital stay. This is not the open surgery of the 1990s.

And here's the framing I really want you to hold onto for the rest of this video: these are NOT competing treatments. They're complementary tools on a spectrum. Some people do best with medications. Some people do best with surgery. And increasingly, some people benefit from both. It's not either/or. Keep that in mind.

The Numbers: Weight Loss Head-to-Head

Alright, let's talk numbers. Because at the end of the day, most people want to know — how much weight will I actually lose?

With GLP-1 medications: semaglutide at the 2.4 milligram dose — that's the Wegovy dose — achieves about 15 percent total body weight loss over 68 weeks. So if you weigh 250 pounds, that's roughly 37 to 38 pounds. In recent real world studies, the real number is a few percentage points less.

Tirzepatide does even better. About 21 percent weight loss at 72 weeks. Same 250-pound person, that's over 50 pounds. That's the most potent medication we have right now. Same thing about a few point drop in effectiveness in real world studies

Now, surgery. Sleeve gastrectomy gets you to about 25 percent weight loss at 12 months. Gastric bypass — about 30 percent. So that same 250-pound person is looking at 62 to 75 pounds lost. That's a big difference.

But here's where it gets really interesting. A large network meta-analysis — this was published in 2026, looked at 30 randomized controlled trials, over 20,000 patients — found that surgery achieved about 10 percent greater total weight loss than GLP-1 medications at less than two years. And that gap held up at two years and beyond, at about a 9 percent difference.

However — and this is a critical nuance — when they looked at tirzepatide specifically and compared it to surgery, the difference was NOT statistically significant. Let that sink in. The newest, most potent medication is getting close to surgical-level weight loss in clinical trials. That's a game-changer for the medication side of this conversation.

There's also a time dynamic here that matters. At six months, the gap between medications and surgery is actually pretty small. But by one year and beyond, surgery starts to pull further ahead. And certain groups see the biggest advantage from surgery — older patients, men, and people with very high starting BMIs.

One more thing I want to be really honest about. These are all averages. Individual responses vary enormously in both groups. Some people on semaglutide lose 25 percent of their weight. Some lose 5 percent. Same with surgery — most people do great, but not everyone hits those average numbers. Your response is going to depend on your biology, your adherence, your lifestyle, a lot of factors.

Beyond the Scale: Metabolic and Cardiovascular Benefits

Now, weight loss is important. Obviously. But what really matters — what your doctor cares about most — is what's happening inside your body. The metabolic changes. The cardiovascular risk. That's where the real life-saving stuff happens.

Let's start with diabetes. If you have type 2 diabetes, surgery is remarkably effective at putting it into remission. The data shows sustained HbA1c reductions of about 1.4 percent at seven years after surgery, with high rates of complete diabetes remission — meaning people come off their diabetes medications entirely. GLP-1 medications also lower blood sugar significantly in the short term, but the effect tends to plateau and weaken over time. One meta-analysis found that over 10 years, surgery reduced HbA1c by about 0.86 percent compared to just 0.23 percent for GLP-1 medications. That's a meaningful difference, especially if you're someone whose diabetes is progressing.

Now, cardiovascular outcomes — this is where it gets really compelling. A 2025 study published in Nature Medicine followed patients for a median of almost six years and found that surgery was associated with a 32 percent lower risk of death from any cause compared to GLP-1 medications. It also showed a 35 percent lower risk of major cardiovascular events — heart attacks, strokes, that kind of thing. And the microvascular benefits were even more dramatic — 47 percent lower risk of kidney disease and 54 percent lower risk of diabetic eye disease.

Another study looked at lifetime cardiovascular risk and found that surgery reduced it by 8.6 percent compared to just 1.7 percent for GLP-1 medications, with bigger improvements in both LDL and HDL cholesterol.

Now — and this is important — I don't want to make it sound like GLP-1 medications have no cardiovascular benefit. They absolutely do. The SELECT trial showed that semaglutide reduced major cardiovascular events by 20 percent in patients who already had established heart disease. That's a proven, significant benefit. These are not zero-benefit medications. Not even close.

There are other benefits worth mentioning too. Both treatments improve sleep apnea. Both can help with joint pain. Semaglutide actually just got FDA approval for treating MASH — that's the liver disease that used to be called fatty liver disease — specifically in patients with liver fibrosis. And both treatments can improve fertility in women with obesity-related reproductive issues.

What Happens When You Stop? Durability and the Chronic Disease Model

This is the segment that I think is the most important for people to really understand. Because the single biggest difference between these two treatments isn't the weight loss numbers. It's what happens over time. Surgery is a one-time anatomical change. Once your stomach is smaller, it stays smaller. Once your digestive tract is rerouted, it stays rerouted. The hormonal changes that surgery creates are largely permanent.

GLP-1 medications require ongoing use. You stop the injection, the effects go away.

And the data on this is really clear. The STEP 1 trial extension followed people who stopped taking semaglutide, and within one year, they regained about two-thirds of the weight they had lost. Two-thirds. The SURMOUNT-4 trial showed similar results with tirzepatide — people who stopped the medication regained about 14 percent of their body weight, while people who stayed on it continued to lose. And it wasn't just the weight that came back. The improvements in blood pressure, cholesterol, blood sugar — those reversed too.

Now, does that mean surgery is perfect? No. Weight regain after surgery is real. It happens. On average, people regain about 7 to 8 kilograms from their lowest weight. And about 10 percent of gastric bypass patients and up to 30 percent of sleeve patients end up with less than 20 percent total body weight loss in the long run. So it's not a magic bullet either.

But here's the exciting part — and this is where the field is really moving. GLP-1 medications can rescue weight regain after surgery. If someone had surgery five years ago and the weight is starting to creep back up, adding a GLP-1 medication can get them back on track without needing a second operation. This is an increasingly common strategy, and the evidence supporting it is growing fast. But more on that in a few minutes.

The bottom line for you is this: if you choose medications, plan for lifelong use. That's not a failure — that's how chronic disease treatment works. You wouldn't stop your blood pressure medication because your blood pressure is normal, right? Same concept. And if you choose surgery, understand that some regain is normal, and medications might be added later. Obesity is a chronic disease either way. The treatment doesn't end — it evolves.

The Real Costs: Financial Comparison

Alright, let's talk money. Because this is a huge factor for a lot of people, and honestly, the landscape here has changed dramatically in just the last year or two.

First, the good news. GLP-1 medications have gotten a LOT cheaper. Between manufacturer price cuts, insurance negotiations, competition between drugs, and the Inflation Reduction Act pushing Medicare to negotiate prices — we're now looking at roughly \$350 to \$450 a month for most people who have coverage or access to discounts. That's a massive drop from where we were. Not long ago, these medications were running \$1,200 to \$1,600 a month out of pocket. So the financial picture has shifted significantly.

But let's do the math. Even at \$400 a month — which is a reasonable middle estimate right now — that's \$4,800 a year. Over five years, that's \$24,000. Over ten years, that's \$48,000. And remember, this is a medication most people need to take for life. If you stop, the weight comes back. So you're looking at a decades-long commitment.

Now compare that to surgery. Surgery has a higher upfront cost — we're talking \$20,000 to \$30,000 depending on the procedure, your location, and your insurance. But it's a one-time cost. There's no monthly bill after that. You'll need follow-up visits and lifelong vitamin supplements, but those costs are relatively small.

One study published in JAMA Surgery found that over just two years, surgery saved about \$11,700 compared to GLP-1 medications — and that was when GLP-1s were priced much higher than they are today. So at current prices, that gap has narrowed. There's no question about that.

Here's the thing, though. Most of the cost-effectiveness studies that have been published were done when GLP-1 medications cost \$13,000 to \$20,000 a year. At those prices, the math was brutal for medications — one analysis found an incremental cost-effectiveness ratio of over \$560,000 per quality-adjusted life year compared to gastric bypass, which is way above what anyone considers acceptable. That same study found GLP-1s would need to cost less than about \$582 a month to be cost-effective versus surgery.

Well, guess what? We're now in that range. At \$350 to \$450 a month, GLP-1 medications are approaching — and in some cases crossing — that cost-effectiveness threshold. The 2026 AHA/ACC guidelines actually acknowledged this, noting that earlier cost-effectiveness models assumed drug prices substantially higher than current costs, and that the comparative cost-effectiveness of surgery versus GLP-1 medications is now genuinely uncertain. That's a big shift in the conversation.

But — and this is a big but — even at lower drug prices, the total healthcare costs tell a more complicated story. A 2026 study in JAMA Network Open followed over 5,400 patients with obesity and diabetes for an average of six and a half years and found that GLP-1 users still had consistently higher overall healthcare costs than surgery patients — about \$109 more per month per patient. And that difference wasn't just the medication itself. It was driven by higher hospitalization costs and higher costs for other medications.

Surgery patients had more dramatic early improvements in weight and blood sugar, and that translated into lower downstream healthcare spending. Another meta-analysis of over 14,500 patients found that at 24 months, out-of-pocket costs were still significantly higher in the GLP-1 group compared to surgery.

So here's how to think about it. The raw drug cost gap has closed substantially. At \$350 to \$450 a month, GLP-1 medications are no longer the financial impossibility they once were. For a lot of people, that's manageable — especially if insurance is covering part of it. But the total cost of care over time — including what happens to your other medications, your hospitalizations, your overall health trajectory — still tends to favor surgery, particularly for people with higher BMIs and diabetes.

Now let's talk about the real-world insurance landscape, because the sticker price isn't the whole story. Insurance coverage for GLP-1 medications is still all over the map. Some private insurers cover them for obesity. Some only cover them for diabetes. Some cover them but with heavy restrictions — prior authorizations, step therapy requirements, lifetime caps. Medicare Part D now covers GLP-1s for diabetes, but coverage for obesity alone is still extremely limited. And even when coverage exists, prior authorization is now required in nearly 100 percent of Medicare Part D plans — that's up from less than 5 percent just a couple of years ago.

For bariatric surgery, coverage has actually gotten better over the years, but it still varies. Some employers specifically exclude it. Many plans require a six-month supervised diet before they'll approve it. It's a process. But once it's approved and done, you're not fighting with your insurance company every month to keep your treatment going.

And here's a cost that people don't think about enough — the cost of stopping. Real-world adherence to GLP-1 medications is much lower than what we see in clinical trials. In practice, only about a third to half of patients are still on the medication at one year, and only about 15 percent at two years. People stop for all kinds of reasons — cost, side effects, insurance changes, shortages.

And when they stop, the weight comes back. The downstream costs of that — diabetes medications, cardiac events, joint replacements, dialysis — those costs can be enormous. With surgery, once it's done, it's done. The anatomical change is permanent regardless of what happens with your insurance.

So the bottom line? GLP-1 medications are more affordable than ever, and the cost argument against them has weakened considerably. But surgery still has a structural financial advantage because it's a one-time investment rather than a lifelong recurring expense. The right choice depends on your individual financial situation, your insurance coverage, and honestly, your confidence in being able to maintain access to the medication long-term.

Risks and Side Effects: An Honest Comparison

Okay, let's be honest about the downsides. Every treatment has them, and you deserve to know what they are.

GLP-1 side effects. The most common one is nausea. Most people experience it, especially when they're first starting or when the dose goes up. The good news is it's usually temporary — it tends to get better over the first few weeks. You might also get vomiting, constipation, or diarrhea. About a third of patients experience some kind of adverse event.

The rarer concerns — and I want to be upfront about these — include pancreatitis, gallbladder disease, and potential GI motility issues. There's also a boxed warning about medullary thyroid carcinoma, though this has mainly been seen in animal studies. If you have a personal or family history of medullary thyroid cancer or a condition called MEN2, these medications are contraindicated. Slow dose titration — starting low and going up gradually — helps minimize most of the side effects.

Now, surgical risks. Let's be clear — modern bariatric surgery is very safe. The mortality rate is about 0.03 to 0.1 percent. That's comparable to having your gallbladder removed. But complications can happen. Early complications include anastomotic leaks — that's where the surgical connection doesn't seal properly — which occurs in about 1 to 7 percent of sleeve patients and 0.6 to 4.4 percent of bypass patients. There's also a risk of postoperative bleeding, about 11 percent, and blood clots.

Late complications are different. With gastric bypass, you can get internal hernias or marginal ulcers — those happen in about 2.5 to 5 percent of patients. And here's something that's really important: after surgery, you need lifelong vitamin and mineral supplementation. B12, iron, calcium, vitamin D, folate, thiamin, and others. Your body's ability to absorb these nutrients changes permanently, especially with bypass. If you don't stay on top of your supplements and get regular blood work, you can develop serious deficiencies.

One thing that applies to both treatments — muscle and bone loss. When you lose a lot of weight quickly, you don't just lose fat. You lose lean muscle mass too. And that matters, especially as you get older. This is why protein intake and resistance training are so important with either approach. Whether you're on a GLP-1 or you've had surgery, you need to be lifting weights and eating enough protein. Period.

One more thing — if you're on a GLP-1 medication and you're going to have any kind of surgery, not just bariatric surgery, you need to tell your anesthesiologist. These medications slow down how fast your stomach empties, which means there might be food still sitting in your stomach when you go under anesthesia. That increases the risk of aspiration. The American Society of Anesthesiologists has guidelines on this — the approach is becoming more personalized now, but it's a conversation you absolutely need to have with your surgical team.

The Power of Both: How GLP-1s Are Being Used WITH Surgery

This is the part of the conversation that I think is the most exciting, and honestly, it's where the future of obesity treatment is heading. Because more and more, the question isn't "surgery OR medication." It's "surgery AND medication — and when?" Let me break this into three parts.

Before surgery. For patients with very high BMIs — especially above 50 — losing some weight before the operation makes the surgery safer. It shrinks the liver, which gives the surgeon better visibility and more room to work. It reduces the overall anesthetic risk. Think of it like training before a marathon — the GLP-1 gets your body in better shape for the surgery itself.

The data backs this up. In patients with a BMI over 50, preoperative GLP-1 use was associated with a 5.5-point BMI reduction compared to 2.9 points in patients who didn't use them. And a 2026 meta-analysis of 10 studies — over 5,400 patients — confirmed that preoperative GLP-1 use produced moderate weight loss before surgery and was generally safe, with no significant increase in postoperative complications.

Now, here's an important nuance. Using a GLP-1 before surgery doesn't seem to improve your long-term weight loss after surgery. The benefit is really about making the operation itself safer and technically easier. It's a preoperative optimization tool, not a long-term weight loss booster.

After surgery — for weight regain. This is where the strongest evidence exists, and where there's the most clinical excitement right now.

Weight regain after bariatric surgery is common. It's not a failure — it's the biology of a chronic disease. Up to 30 percent of sleeve gastrectomy patients may not achieve or maintain 20 percent total body weight loss long-term. Previously, the main option for these patients was revisional surgery — a second, more complex operation. But now there's another option.

A JAMA review looked at nearly 3,000 patients across 29 studies and found that adding semaglutide after surgery produced an additional 10.3 percent total body weight loss. Tirzepatide did even better — 15.5 percent additional loss. These are patients who had already had surgery and were regaining weight, and the medications got them back on track.

The BARI-OPTIMISE trial — this was a proper randomized controlled trial — took 70 patients who had a suboptimal response to surgery and gave half of them liraglutide and half a placebo. Over 24 weeks, the liraglutide group lost an additional 8.8 percent of their body weight. The placebo group? Half a percent. That's a difference of about 10 kilograms — 22 pounds. That's meaningful.

And the benefits go beyond weight. GLP-1 medications after surgery also improved triglycerides, cholesterol, blood sugar, and liver enzymes. The side effects were mostly GI-related — nausea in about 23 percent, constipation in 10 percent, vomiting in 6 percent — but only 3 percent of patients had to stop the medication because of side effects. That's a very acceptable tolerability profile.

So if you've had bariatric surgery and the weight is creeping back, a GLP-1 medication may be able to get you back on track without needing a second surgery. That's a big deal.

But — and I have to be transparent here — a few caveats. All the tirzepatide data in post-bariatric patients is observational so far. There are no randomized controlled trials yet specifically for tirzepatide after surgery. The sample sizes are small. We don't know how long the effect lasts if you stop the medication — weight regain after discontinuation is highly likely, just like in non-surgical patients. And cost is a real barrier — insurance coverage for GLP-1 use after bariatric surgery is inconsistent.

Safety when combining. If you're on a GLP-1 after surgery, nutritional monitoring becomes even more critical. You're combining the appetite-suppressing effects of the medication with the restrictive and sometimes malabsorptive anatomy from surgery. That creates a compounded risk of nutritional deficiency. You need structured monitoring for iron, B12, folate, calcium, vitamin D, zinc, and copper. You need DEXA scans to check your bone density. And the data shows significant decreases in lean muscle mass and bone mineral density with GLP-1 use after surgery — which means resistance training and getting at least 60 to 80 grams of protein per day are absolutely essential.

If you're on a GLP-1 after surgery, you MUST be working with a team — your surgeon, your endocrinologist, and a dietitian — to make sure you're getting the nutrients your body needs.

When to start. Most studies have started GLP-1 medications at least 12 months after surgery, targeting patients who've already shown weight regain or insufficient loss. There's growing interest in starting them earlier — when weight loss first plateaus rather than waiting for regain — but the evidence for that approach is still limited. What we do know is that GLP-1 use after bariatric surgery is increasing rapidly, most commonly starting after the second postoperative year, driven by rising BMI. It's more common among women and those with more comorbidities.

The takeaway? The question isn't just "surgery or medication" anymore. It's "surgery and medication, and when?" That's the future of obesity treatment.

How to Decide Which Path Is Right for You

Alright, so you've heard all the data. Now let's make it practical. How do you actually decide which path is right for you? Let me walk you through a framework based on the evidence.

BMI matters. If your BMI is between 27 and 35 and you have weight-related health conditions — diabetes, high blood pressure, sleep apnea — GLP-1 medications are generally considered first-line. Surgery can be considered if your BMI is 30 to 35 with metabolic disease and you haven't responded well enough to medications.

If your BMI is 35 or above, both options are appropriate. Surgery should be actively discussed at this point — not reserved as a last resort. That's what the guidelines say. If your BMI is 40 or above, surgery offers the greatest relative benefit and should be strongly considered. The data is very clear on this.

Diabetes status matters. If you have type 2 diabetes that's relatively new — shorter duration, high blood sugar, maybe you're already on insulin — surgery may offer the best chance of putting that diabetes into remission. If your diabetes is well-controlled or you don't have diabetes at all, GLP-1 medications may be sufficient. And here's an interesting finding — if you've had diabetes for more than 10 years, the mortality benefit of surgery over GLP-1 medications actually diminishes. The advantage is biggest when diabetes is caught and treated aggressively early.

Your personal profile matters. The data shows that older patients, men, and people with very high baseline BMIs tend to see the greatest advantage from surgery compared to medications.

Lifestyle and preference factors matter too. Are you comfortable with giving yourself a weekly injection for the rest of your life? Or would you rather have a one-time procedure and be done with it? Are you willing to commit to lifelong vitamin supplementation — because surgery requires that?

Do you have needle phobia? There's actually an oral version of semaglutide now, so that's an option. Do you have access to a high-volume bariatric surgery center? Outcomes are significantly better at centers that do a lot of these operations versus places that only do a handful a year.

And what's your financial and insurance situation? At current prices, GLP-1 medications are more affordable than ever — but it's still a monthly cost that adds up over years and decades, versus a one-time surgical investment.

Contraindications. There are some situations where one option is off the table. Surgery may not be appropriate if you have certain anatomical issues — a large hiatal hernia, active gastric ulcers — or if your anesthetic risk is too high. GLP-1 medications are contraindicated if you have a personal or family history of medullary thyroid carcinoma or a genetic condition called MEN2.

And here's the message I really want to land. For a lot of people, it's not either/or. Many patients benefit from a combined or sequential approach. Maybe you start with a GLP-1 to lose some weight and improve your health, and then move to surgery when you're in a better position for the operation.

Or maybe you have surgery first, do great for a few years, and then add a GLP-1 later when some weight starts to come back. The evidence supports both of those paths. The best obesity treatment is the one that's tailored to you — and it might change over time. That's okay.

That's actually how good medicine works.

What to Ask Your Doctor

Okay. So you've now got a solid understanding of both treatments. But knowledge only matters if you use it. So here are the specific questions I want you to bring to your next doctor's appointment. Write these down. Screenshot this. Whatever you need to do.

Number one. "Based on my BMI, my health conditions, and my goals — am I a candidate for surgery, medications, or both?" Don't let anyone tell you there's only one option without explaining why. Number two. "What percentage of weight loss can I realistically expect with each option?" Not the best-case scenario. Not the clinical trial numbers. What's realistic for someone like me?

Number three. "What does my insurance actually cover — and what will I be paying out of pocket?" Get specific. Ask about prior authorizations. Ask about how long approval takes. Ask what happens if your coverage changes.

Number four. "If I start a GLP-1, what's the plan if I need to stop?" Whether it's because of cost, side effects, a shortage, or a change in insurance — what's the backup plan? Because stopping without a plan is how people end up regaining everything.

Number five. "If I'm considering surgery, what's your center's complication rate and how many of these procedures do you do per year?" Volume matters. A surgeon who does 200 of these a year is going to have different outcomes than one who does 20. Don't be afraid to ask.

Number six. "How will we monitor for nutritional deficiencies and side effects long-term?" This applies to both treatments, but especially surgery. You need a plan for blood work, supplements, bone density — the whole picture.

And number seven. "Can these treatments be combined if one alone isn't enough?" If your doctor doesn't know the answer to this question, or dismisses it, that might tell you something about whether they're up to date on the latest evidence. These aren't confrontational questions. They're informed questions. And any good doctor will respect you for asking them.

Final Thoughts

Alright. Let's bring it all together. Here's what I want you to walk away with. Obesity is not a character flaw. It's not a lack of discipline. It's a chronic, biological disease — driven by hormones, genetics, and brain chemistry. And just like any other chronic disease, it deserves real medical treatment. Not shame. Not "just eat less and move more." Real treatment.

And right now, we have two incredibly powerful treatments available. GLP-1 medications — which can help you lose 15 to 21 percent of your body weight, improve your heart health, and are more affordable and accessible than they've ever been. And bariatric surgery — which can help you lose 25 to 30 percent, has the strongest long-term data, the best diabetes remission rates, and is a one-time procedure that doesn't require lifelong medication.

Neither one is perfect. Both have trade-offs. And the "best" one depends entirely on who you are — your body, your health, your diabetes status, your BMI, your finances, your preferences, your life.

What I hope this video has done is given you the information you need to have a real conversation with your doctor. Not a conversation where you're just nodding along. A conversation where you're asking the right questions, understanding the answers, and making a decision that's truly informed.

And remember — it doesn't have to be one or the other. The future of obesity treatment is personalized. It's combination therapy. It's starting with one approach and adjusting over time. It's treating this like the chronic disease it is, with the same seriousness and the same long-term commitment you'd give to managing diabetes or heart disease.

You now know more about these treatments than most people. Honestly, more than a lot of people who have opinions about them on the internet. Take this information. Talk to your doctor. And make the decision that's right for your life.

If you found this video helpful be sure and subscribe so you can keep an eye out for the next one where I'll be talking about more information about metabolic disease and bariatric surgery. Real science real surgery real results